We are live on ! Find out more
TC

Trilogy Capital Portfolio holdings

AUM $2.58B
1-Year Est. Return 22.97%
This Fund
S&P 500
This Quarter Est. Return
-10.66%
1 Year Est. Return
+22.97%
3 Year Est. Return
+54.11%
5 Year Est. Return
+45.31%
10 Year Est. Return
AUM
$1.15B
AUM Growth
-$244M
Cap. Flow
-$101M
Cap. Flow %
-8.81%
Top 10 Hldgs %
51.75%
Holding
181
New
15
Increased
102
Reduced
42
Closed
22
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TOTL icon
126
State Street DoubleLine Total Return Tactical ETF
TOTL
$4.14B
$371K 0.03%
8,784
+113
+1% +$4.87K
PEP icon
127
PepsiCo
PEP
$185B
$361K 0.03%
2,166
+164
+8% +$27.6K
SRLN icon
128
State Street Blackstone Senior Loan ETF
SRLN
$5.31B
$358K 0.03%
8,605
+1,002
+13% +$43.5K
PRFZ icon
129
Invesco FTSE RAFI US 1500 Small-Mid ETF
PRFZ
$2.77B
$339K 0.03%
11,045
+5
+0% +$166
SPHQ icon
130
Invesco S&P 500 Quality ETF
SPHQ
$19.3B
$339K 0.03%
8,069
+3,062
+61% +$141K
ARKK icon
131
ARK Innovation ETF
ARKK
$6.14B
$323K 0.03%
8,089
-284
-3% -$13.5K
VMBS icon
132
Vanguard Mortgage-Backed Securities ETF
VMBS
$15.5B
$319K 0.03%
6,667
+10
+0.2% +$482
MRK icon
133
Merck
MRK
$307B
$318K 0.03%
3,493
+285
+9% +$25.3K
IIGD icon
134
Invesco Investment Grade Defensive ETF
IIGD
$26.8M
$298K 0.03%
12,260
+660
+6% +$16.2K
BMY icon
135
Bristol-Myers Squibb
BMY
$123B
$286K 0.02%
3,712
+221
+6% +$16.8K
IGIB icon
136
iShares 5-10 Year Investment Grade Corporate Bond ETF
IGIB
$18.5B
$282K 0.02%
5,515
-1,283
-19% -$66.9K
IEMG icon
137
iShares Core MSCI Emerging Markets ETF
IEMG
$149B
$270K 0.02%
5,504
+4
+0.1% +$207
JNJ icon
138
Johnson & Johnson
JNJ
$599B
$267K 0.02%
1,506
-84
-5% -$15K
CVS icon
139
CVS Health
CVS
$137B
$258K 0.02%
2,784
+529
+23% +$51.6K
AMZN icon
140
Amazon
AMZN
$2.69T
$247K 0.02%
2,321
+241
+12% +$30.2K
ULST icon
141
State Street Ultra Short Term Bond ETF
ULST
$527M
$243K 0.02%
+6,100
New +$244K
TSLA icon
142
Tesla
TSLA
$1.39T
$240K 0.02%
1,068
+57
+6% +$15.6K
XMLV icon
143
Invesco S&P MidCap Low Volatility ETF
XMLV
$750M
$240K 0.02%
4,674
-30
-0.6% -$1.61K
TSN icon
144
Tyson Foods
TSN
$20.4B
$237K 0.02%
2,757
+515
+23% +$46.1K
DES icon
145
WisdomTree US SmallCap Dividend Fund
DES
$2.19B
$234K 0.02%
+8,282
New +$249K
IUSB icon
146
iShares Core Universal USD Bond ETF
IUSB
$42.8B
$230K 0.02%
4,909
+348
+8% +$16.5K
AOM icon
147
iShares Core Moderate Allocation ETF
AOM
$1.76B
$227K 0.02%
5,835
-2,975
-34% -$120K
EFV icon
148
iShares MSCI EAFE Value ETF
EFV
$27.2B
$222K 0.02%
5,126
+407
+9% +$19.4K
IEFA icon
149
iShares Core MSCI EAFE ETF
IEFA
$185B
$220K 0.02%
3,732
+6
+0.2% +$385
PFE icon
150
Pfizer
PFE
$141B
$218K 0.02%
+4,165
New +$212K

Similar funds

Trilogy Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Trilogy Capital held 181 positions worth $1.15B, down 18% from $1.39B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Trilogy Capital withdrew a net $101M in Q2 2022, closing 22 positions and reducing 42 holdings. Its most notable exit was State Street Consumer Discretionary Select Sector SPDR ETF, an estimated $24.4M position sold in full.

By sector, the portfolio is most concentrated in Utilities at 1.1% of assets, up from 0.76% a quarter earlier, followed by Healthcare and Consumer Staples.

Against the trend, Trilogy Capital opened a new position in State Street SPDR S&P 600 Small Cap Value ETF worth $18.3M.

  • Trilogy Capital's largest Q2 2022 buy was State Street SPDR S&P 600 Small Cap Value ETF: 252,188 shares worth $18.3M.
  • Trilogy Capital added most to iShares Core Conservative Allocation ETF in Q2 2022, an estimated $45.5M increase.
  • Trilogy Capital's biggest Q2 2022 reduction was State Street SPDR Portfolio S&P 500 Growth ETF, cutting an estimated $34.2M.
  • Trilogy Capital fully exited State Street Consumer Discretionary Select Sector SPDR ETF in Q2 2022, selling an estimated $24.4M.
  • Trilogy Capital's ten largest holdings make up 52% of its $1.15B portfolio in Q2 2022.
  • Trilogy Capital opened 15 new positions and closed 22 in Q2 2022.
  • Trilogy Capital's portfolio value fell 18% quarter-over-quarter to $1.15B.

Based on Trilogy Capital's 13F filing for Q2 2022, filed 20 Jul 2022.